Drug Trial Radar · NCT05503264
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
122
Actual
Start
Sep 27, 2022
Primary completion
Dec 16, 2026
Study completion Dec 14, 2028
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Chugai Pharmaceutical
- First posted
- Aug 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
Conditions
- NMDAR Autoimmune Encephalitis
- LGI1 Autoimmune Encephalitis
Interventions
SatralizumabDrug
In Part 1, study drug will be administered after all other study-related procedures have been performed at a site visit at Weeks 0, 2, 4, and every 4 weeks (Q4W) thereafter. Participants will receive satralizumab according to body weight, administered as subcutaneous (SC) injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit. In Part 2, participants will be asked to choose from one of the following options: Option 1: continue on randomized, double-blind study drug; Option 2: start open-label satralizumab based on body weight; Option 3: stop study treatment and continue follow-up assessments. As of Protocol Version 6, participants in the NMDAR cohort who chose Option 1 will transition to either Option 2 or Option 3 at the time of the primary analysis.
PlaceboOther
Satralizumab placebo prefilled syringe (PFS) is identical in composition to satralizumab PFS, but does not contain the satralizumab active ingredient and will be identical in appearance and packaging to satralizumab. A PFS (assembled with an needle safety device \[NSD\] and extended finger flange) filled with 0.5 milliliters (mL) of solution, corresponding to 60 milligrams (mg) satralizumab, may be used in Part 2 once it becomes available at the study site.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Proportion of Participants in NMDAR AIE Cohort With Modified Rankin Scale (mRS) Score Improvement ≥ 1 From Baseline and no Use of Rescue Therapy at Week 24Time frame: Baseline up to Week 24
- Part 1: Proportion of Participants in LGI1 AIE Cohort With mRS Score Improvement ≥ 1 From Baseline and no Use of Rescue Therapy at Week 52Time frame: Baseline up to Week 52
- Part 2: Percentage of Participants With Adverse Events (AEs)Time frame: From Week 52 up to 4 years
Locations
56 sites in 15 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Hoag Memorial Hospital
Newport Beach, California
UCSF- Multiple Sclerosis Centre
San Francisco, California
University of Colorado
Aurora, Colorado
Childrens National Health Center
Washington D.C., District of Columbia
Brigham and Women's Hospital Department of Neurology
Boston, Massachusetts
Mayo Clinic - Rochester
Rochester, Minnesota
NYU-Langone Medical Center
New York, New York
University Hospitals of Cleveland
Cleveland, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio
Medical College of Wisconsin
Milwaukee, Wisconsin
Hospital Ramos Mejía
CABA, Argentina
Hospital Britanico
Ciudad Autonoma Bs As, Argentina
Sanatorio del Sur S.A.
San Miguel de Tucumán, Argentina
Hospital Geral de Fortaleza
Fortaleza, Ceará, Brazil
CEDOES - Diagnóstico e Pesquisa
Vitória, Espírito Santo, Brazil
Instituto de Neurologia de Curitiba
Curitiba, Paraná, Brazil
Centro de Pesquisas Clinicas
São Paulo, São Paulo, Brazil
Hospital Israelita Albert Einstein
São Paulo, São Paulo, Brazil
Beijing Children's Hospital, Capital Medical University
Beijing, China
Beijing Tongren Hospital
Beijing, China
Beijing Tiantan Hospital,Capital Medical University
Beijing, China
West China Hospital - Sichuan University
Chengdu, China
Fujian Medical University Union Hospital
Fuzhou, China
Affiliated Hospital of Jining Medical University
Jining, China
Huashan Hospital, Fudan University
Shanghai, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China
Fakultni nemocnice v Motole
Prague, Czechia
Odense Universitetshospital, Neurologisk Afdeling N
Odense C, Denmark
Hopital neurologique Pierre Wertheimer - CHU Lyon
Bron, France
Hopital Pitié Salpétrière - CHU
Paris, France
Komfo Anokye Teaching Hospital
Kumasi, Ghana
Hadassah University Hospital Ein Kerem
Jerusalem, Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
A. O. U. Federico II
Naples, Campania, Italy
Irccs A.O.U.San Martino Ist
Genoa, Liguria, Italy
Fondazione Istituto Neurologico Mondino IRCCS
Pavia, Lombardy, Italy
AOU Policlinico Giaccone
Palermo, Sicily, Italy
Fujita Health University Hospital
Aichi, Japan
Chiba University Hospital
Chiba, Japan
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.